Download PDF
Open Access
CC BY 4.0 · Surg J (N Y) 2018; 04(04): e197-e200
DOI: 10.1055/s-0038-1673662
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Outcomes of Biliointestinal Bypass among Iranian Obese Patients

Authors

  • Seyed Morteza Mousavi Naeini

    1   General Surgeon, Private Practice, Tehran, Iran

  • Alireza Khalaj

    2   Department of Surgery, Shahed University of Medical Sciences, Tehran, Iran

  • Ali Abbaszadeh-Kasbi

    3   School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

  • Seyed Rouhollah Miri

    4   Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran
Further Information

Publication History

04 May 2018

04 September 2018

Publication Date:
18 October 2018 (online)

Also available at
  Permissions and Reprints

Abstract

Background There are several surgical approaches to treat obesity not cured with medical approaches. Each method has its advantages and complications. In here, we have conducted a study to evaluate complications of biliointestinal bypass surgery (BIBP).

Methods A prospective study was conducted in a private hospital from 2002 to 2016. Those patients, not previously operated for morbid obesity, were eligible. Mean follow-up period was 89 months ( ± 54 months; range: 73–108 months). Main outcome measures were weight, BMI (body mass index), concentrations of blood lipids and glucose, liver transaminases, and obesity-related comorbidities and complications.

Results Twenty-three consecutive patients with morbid obesity, including 16 women (69.7%) and seven men (31.3%) with mean age 38.47 ± 10 years (range: 26–57 years) underwent surgery. At the end of follow-up period, a mean BMI reduction of 12.2 kg/m2 kg/m2 (p < 0.001)] was observed. An excess weight loss (EWL) of 63% ( ± 34) was achieved at the end of the study. Additionally, total cholesterol and triglyceride levels decreased postoperative significantly. The main long-term complications were flatulence (60%), borborygmus (47.8%), mal odorous stool (30.4%), and diarrhea (21.7%). Revision rate was 4.34%. There were no cases with irreversible hepatic injury, deaths due to the surgery, or progressive renal failure.

Conclusion BIBP seems to be a safe, easily reversible, and one of valid therapeutic approaches in morbidly obese patients. BIBP has the potential to achieve durable weight loss and offers an improved quality of life.

Keywords

obesity - BIBP - efficacy - outcome